Meeting
2022 ASCO Annual Meeting
Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.
Authors
Manish Sharma
START Midwest, Grand Rapids, MI
Manish Sharma , Babar Bashir , Dejan Juric , Erika P. Hamilton , Kyriakos P. Papadopoulos , Susanna Varkey Ulahannan , Geoffrey Shapiro , Vaibhav Sahai , Niharika B. Mettu , Monica M. Mita , Mehmet Akce , Jessica Tao , Graeme Hodgson , Nan Ke , Susan Henry , Sofia Paul , Neha Lodaya , Catherine Madigan , David A. Roth , Virginia Klimek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT04247126
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4180)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4180
Abstract #
TPS4180
Poster Bd #
155b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).
First Author: Rishi Surana
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
First Author: Andrew L. Coveler
Poster
2021 ASCO Annual Meeting
Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Gang Jin